NCT05200208Completed
Improving Sleep and Cognition in Alzheimer's Disease
Improving Sleep and Cognition in Alzheimer's Disease: A Pilot RCT of Citicoline
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
Cognitive disorders include such things as memory disorders, mild cognitive impairment, and Alzheimer's disease (AD). The purpose of the study is to learn more about whether a dietary citicoline supplement will improve sleep and cognition. Sleep disturbances currently afflict approximately 25-44% of those with AD, resulting in decreased quality of life for those with AD and their caregivers and are a major driver of institutionalization. Previous studies have tested this dietary supplement in Alzheimer's disease and shown that citicoline may improve cognitive decline. The research team would like to see if citicoline will also improve sleep. The citicoline that will be provided is made by Kyowa Hakko Pharma Chemical Company. This dietary supplement has been tested for Alzheimer's disease and found to be well tolerated. Citicoline has previously been used safely in other Alzheimer's disease populations at the same dosage.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 18 Jan 2022
- Start date
- 27 Jul 2022
- Primary completion date
- 21 Dec 2025
- Lead sponsor
- Emory University
- Diseases
- Alzheimer disease
- NCT number
- NCT05200208
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 27 Jul 2022 to the primary completion date, 21 Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Epilepsy or head trauma resulting in unconsciousness in the past two years
- Presence of chronic obstructive pulmonary disease, asthma, severe cardiac insufficiency (congestive heart failure, myocardial infarction), type I diabetes, vitamin B12 or folic acid deficiency, liver cirrhosis, thyroid dysfunction, rheumatoid arthritis, chronic renal failure, and/or psychiatric disorders, obstructive sleep apnea, restless legs syndrome or periodic limb movement disorder
- History of alcohol dependence and medication abuse
Other
- No telephone access
- Night shift workers or those in situations where they regularly experience jet lag, or have irregular work schedules, since circadian misalignment may alter markers of inflammation
Who the study is looking for
- Participants who are diagnosed with AD and confirmed from the medical record.
- At least 18 years of age living within the continental United States
- Read and understand English
- Have Internet and email access (this criterion applies to the legally authorized representatives)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Goizueta Alzheimer's Disease Research Center Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory University School of Nursing Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.